Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
$OKYO The gaining | mfayman | investorshub | 09/29/2023 4:25:34 AM |
short data if anyone is interested | Pisd | investorshub | 09/29/2023 2:27:26 AM |
bears are running | glenn1919 | investorshub | 09/29/2023 1:47:11 AM |
$OKYO bears and bulls | mfayman | investorshub | 09/29/2023 12:27:23 AM |
where is the squeeze? | Count Crypto | investorshub | 09/28/2023 11:39:05 PM |
short squeeze article | mfayman | investorshub | 09/28/2023 9:05:57 PM |
$OKYO Price trading up | mfayman | investorshub | 09/28/2023 8:43:11 PM |
$OKYO MomentumIts now up | mfayman | investorshub | 09/28/2023 8:24:26 PM |
MomentumIts trading | mfayman | investorshub | 09/28/2023 5:49:10 PM |
$OKYO Price now | mfayman | investorshub | 09/28/2023 4:12:11 PM |
Lets go go go go... Up up and away we go. | mfayman | investorshub | 09/28/2023 3:33:57 PM |
are we finally gonna see some action | Boris the Spider | investorshub | 09/28/2023 2:38:44 PM |
great article | mfayman | investorshub | 09/28/2023 1:49:57 PM |
$OKYO Price trading | Sirpeter | investorshub | 09/28/2023 1:26:03 PM |
$OKYO Price gaining | mfayman | investorshub | 09/28/2023 1:16:25 PM |
$OKYO MomentumIts gaining last trade up | mfayman | investorshub | 09/28/2023 12:57:01 PM |
Do we have a winner?Turn around time? | StocksNcash | investorshub | 09/28/2023 12:43:30 PM |
$OKYO MomentumIts gaining | mfayman | investorshub | 09/28/2023 12:25:59 PM |
$OKYO MomentumIts trading up | mfayman | investorshub | 09/28/2023 11:26:30 AM |
$OKYO is it bear time? Or do we go bull? | mfayman | investorshub | 09/28/2023 10:26:19 AM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...